Trials to achieve healthy outcomes for extremely premature
babies are challenging. We work with clinicians through global
partnerships, aiming to find cost-effective treatments that will
reduce infant mortality and illness.
Our aim is to investigate areas of need such neonatal
infection, oxygen therapy and simple cost effective measures to
reduce neonatal problems.
BOOSTII (Benefits of Oxygen Saturation
Targeting, trial II) will ascertain which of two oxygen saturation
ranges is better for very premature babies. Oxygen is the most
common therapy for preterm infants. Doctors and nurses do not know
the safe and effective level of oxygenation for these babies.
Higher oxygen levels may increase retinopathy of prematurity and
respiratory problems, but lower oxygen levels may affect other
long-term outcomes. BOOST II has recruited 1135 infants
in Australia (a total of 1475 with the recruitment by our
colleagues in New Zealand). Go to the BOOSTII homepage here.
Placental Transfusion Study (APTS) will determine whether
a 60-second delay in clamping and cutting the cord can improve the
baby's blood flow to the brain and gut, reduce the need for donor
blood, and reduce rates of infection, retinopathy, poor
growth, death and disability in babies born more than 10 weeks
The data from our latest trials are being combined with data
from similar trials in other countries for prospective
meta-analysis of data from many thousands of
patients. We have participated or taken a lead in setting
up networks of investigators who are making this happen.
The INIS trial (International Neonatal
Immunotherapy Study) assessed the effects of nonspecific
intravenous immunoglobulin in addition to antibiotics in babies
with severe infections. This trial is now closed after enrolling
just under 3500 infants. Our global partners are in New
Zealand, the United Kingdom and Argentina.